LENSAR Inc. (LNSR)
13.91
0.16 (1.16%)
At close: Apr 17, 2025, 3:59 PM
13.88
-0.19%
After-hours: Apr 17, 2025, 04:20 PM EDT
Company Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.
Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
The company was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR Inc.
| Country | United States |
| IPO Date | Oct 2, 2020 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Nicholas T. Curtis |
Contact Details
Address: 2800 Discovery Drive Orlando, Florida United States | |
| Website | https://www.lensar.com |
Stock Details
| Ticker Symbol | LNSR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001320350 |
| CUSIP Number | 52634L108 |
| ISIN Number | US52634L1089 |
| Employer ID | 32-0125724 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Nicholas T. Curtis | President, Chief Executive Officer & Director |
| Alan B. Connaughton | Chief Operating Officer |
| Thomas R. Staab II, CPA | Chief Financial Officer & Secretary |
| Kendra W. Wong | Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Mar 25, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 24, 2025 | DFAN14A | Filing |
| Mar 24, 2025 | DEFA14A | Filing |
| Mar 24, 2025 | DEFA14A | Filing |
| Mar 24, 2025 | 8-K | Current Report |
| Feb 28, 2025 | S-8 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 4 | Filing |